Sam Chun Dang Pharm Sam Chun Dang Pharm said it terminated the exclusive Japan distribution and supply agreement for the age-related macular degeneration biosimilar SCD411 by mutual agreement on November 2, 2026.

Supply ContractFiled Nov 2, 2026

Unofficial English translation by ChickenStock; the Korean original prevails. Korean page · Original filing on DART ↗

Highlights

Translated AI summary

The company said it has completed the development and Japanese product approval procedures for SCD411 and terminated the agreement by mutual consent to shift to a structure in which it holds the product approval in its own name and to reorganize its Japanese sales partners. The company said it has no obligation to pay penalties or damages due to the termination. The accounting treatment of the termination may change depending on the results of the external auditor's review.

The counterparty is SENJU Pharmaceutical Co., Ltd. of Japan, and the termination was by mutual agreement.
The company said the upfront payments and milestones received to date, totaling $17,200,000 (about KRW 23 billion), will not be refunded.
The company said it will pay $4,000,000 (about KRW 5.3 billion) as compensation for the recovery of the exclusive distribution rights, and that it will not receive the remaining milestones due to the termination.
The company said it signed a new exclusive Japan distribution and supply agreement for SCD411 with Daiichi Sankyo Espha Co., Ltd. of Japan on the same day.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Total upfront payments and milestones: $17,200,000 (about KRW 23 billion)Exact amount: $17,200,000 (about KRW 23,000,000,000)
Compensation for recovery of distribution rights: $4,000,000 (about KRW 5.3 billion)Exact amount: $4,000,000 (about KRW 5,300,000,000)
Termination date: November 2, 2026
Original contract signing date: March 26, 2019

Filing facts

Filing type: Supply Contract
Report name: Material Management Information for Investment Decisions
Filed: Nov 2, 2026
Receipt number: 20261102900593

Sam Chun Dang Pharm stock page →Korean page →Original filing on DART ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.